Medicine and Dentistry
Surgery
100%
Pancreaticoduodenectomy
78%
Pancreas Cancer
77%
Pancreas Adenocarcinoma
71%
Neoplasm
59%
Overall Survival
53%
Cytoreductive Surgery
44%
Surgeon
42%
Malignant Neoplasm
41%
Disease
33%
Distal Pancreatectomy
32%
Autophagy
31%
Learning Curve
29%
Neoadjuvant Therapy
26%
Robot-Assisted Surgery
25%
Pancreas Fistula
25%
Adenocarcinoma
24%
Advanced Glycation End Product Receptor
21%
Pancreatectomy
21%
Carcinomatous Peritonitis
21%
Metastatic Carcinoma
20%
Operation Duration
18%
Gemcitabine
18%
Health Care Cost
18%
Surgical Oncology
16%
Colorectal Cancer
16%
Hyperthermic Intraperitoneal Chemotherapy
16%
Peritoneum Metastasis
16%
Pancreatic Surgery
16%
Cancer
15%
Hazard Ratio
15%
Bleeding
14%
Stomach Cancer
13%
Tumor Cell
13%
Stereotactic Body Radiation Therapy
13%
Progression Free Survival
12%
Recurrent Disease
12%
Pancreatic Cysts
12%
Proportional Hazards Model
11%
Postoperative Complication
11%
CA 19-9 Antigen
11%
Carcinogenesis
10%
Cell Death
10%
General Surgery
10%
Biological Marker
10%
Odds Ratio
10%
Carcinosis
9%
Adjuvant Therapy
9%
Pseudomyxoma Peritonei
9%
Acute Pancreatitis
9%
Keyphrases
Pancreatic Cancer
32%
High Mobility Group Box 1 (HMGB1)
29%
Pancreaticoduodenectomy
24%
Autophagy
23%
Pancreatic Adenocarcinoma
22%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
22%
Cytoreductive Surgery
22%
Overall Survival
20%
Pancreatic Ductal Adenocarcinoma
18%
Receptor for Advanced Glycation End Products
15%
Resectable Pancreatic Cancer
15%
Chemotherapy
14%
Laparoscopic Pancreaticoduodenectomy
14%
Resection
12%
Carbohydrate Antigen 19-9 (CA19-9)
11%
Gemcitabine
10%
Confidence Interval
10%
Surgeons
10%
Peritoneal Metastasis
9%
Apoptosis
9%
Adjuvant Therapy
8%
Postoperative Outcomes
8%
Robotics
8%
Neoadjuvant Therapy
8%
Peritoneal Carcinomatosis
8%
Median Overall Survival
7%
Hazard Ratio
7%
Borderline Resectable
7%
Pancreatic Cyst
7%
Tumor
7%
Stereotactic Body Radiotherapy
7%
Laparoscopic Distal Pancreatectomy
7%
Operative Time
7%
Carcinomatosis
7%
Retrospective Review
6%
Minimally Invasive Distal Pancreatectomy
6%
Major Complications
6%
Damage-associated Molecular Patterns
6%
Surgical Resection
6%
FOLFIRINOX
6%
Learning Curve
6%
Robotic Approach
6%
Systemic Chemotherapy
6%
Postoperative Pancreatic Fistula
6%
Tumor Microenvironment
6%
Colorectal Cancer
6%
Ferroptosis
6%
Local Anesthesia
6%
Improved Survival
6%
Tumor Protein p53 (TP53)
6%
